DUBLIN, April 24, 2019 /PRNewswire/ -- Alkermes
plc (Nasdaq: ALKS) today announced that C. Todd Nichols, an executive with more than two
decades of extensive commercial experience in the biopharmaceutical
sector, will become the company's Senior Vice President of Sales
and Marketing effective May 13,
2019. He will serve on the Alkermes executive management team
and report to Richard Pops, the company's Chief Executive
Officer.
"We are pleased to welcome Todd to the Alkermes team. His skills
and experience as a proven commercial leader will be important
assets to our organization," said Pops. "Todd brings extensive
industry knowledge, proven leadership and strategic insights that
will be of great value to the company as we continue to
commercialize important medicines that are designed to address
the unmet needs and challenges of people living with debilitating
diseases."
Mr. Nichols most recently held the position of Vice President,
Marketing and Sales, Inflammation and Immunology at Celgene, where
he was responsible for developing and managing all aspects of U.S.
commercial planning, brand P&L, strategy development,
go-to-market modeling and launch execution for ozanimod.
"I am excited to join a company with strong leadership,
dedicated employees and that is rooted in its mission to make a
positive impact on patients struggling with central nervous system
(CNS) disorders," said Mr. Nichols. "I look forward to working with
my new colleagues as the company continues to evolve to meet the
needs of a complex treatment landscape."
Mr. Nichols began his career in 1997 at Schering-Plough
(acquired by Merck in 2009), where he held a variety of sales and
marketing positions across multiple therapeutic franchises. While
at Merck, Mr. Nichols served in numerous senior roles including
Vice President and Head of the U.S. Vaccine Business Unit. Mr.
Nichols joined Biogen in 2014 as Vice President, U.S. Sales and
Field Operations, and achieved record sales for three consecutive
years.
He holds a bachelor's degree in accounting from Elon College.
About Alkermes
Alkermes plc is a fully
integrated, global biopharmaceutical company developing innovative
medicines for the treatment of central nervous system (CNS)
diseases. The company has a diversified commercial product
portfolio and a substantial clinical pipeline of product candidates
for chronic diseases that include schizophrenia, depression,
addiction, multiple sclerosis and oncology. Headquartered in
Dublin, Ireland, Alkermes plc has
an R&D center in Waltham,
Massachusetts; a research and manufacturing facility in
Athlone, Ireland; and a
manufacturing facility in Wilmington,
Ohio. For more information, please visit Alkermes' website
at www.alkermes.com.
Note Regarding Forward-Looking Statements
Certain
statements set forth in this press release constitute
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including,
but not limited to, statements concerning: the company's future
performance, business plans or prospects, and expected growth; and
the potential therapeutic and commercial value of the company's
products. The company cautions that forward-looking statements are
inherently uncertain. Although the company believes that such
statements are based on reasonable assumptions within the bounds of
its knowledge of its business and operations, the forward-looking
statements are neither promises nor guarantees and they are
necessarily subject to a high degree of uncertainty and risk.
Actual performance and results may differ materially from those
expressed or implied in the forward-looking statements due to
various risks and uncertainties, including those risks and
uncertainties described under the heading "Risk Factors" in the
company's Annual Report on Form 10-K for the year
ended December 31, 2018 and in subsequent filings made by
the company with the U.S. Securities and Exchange
Commission (SEC), which are available on
the SEC's website at www.sec.gov. Existing and
prospective investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
they are made. The information contained in this press release is
provided by the company as of the date hereof, and, except as
required by law, the company disclaims any intention or
responsibility for updating or revising any forward-looking
statements contained in this press release.
Alkermes
Contacts:
|
|
|
For
Investors:
|
Sandy
Coombs,
|
+1 781 609
6377
|
For Media:
|
Matthew
Henson,
|
+1 781 609
6637
|
Logo -
https://mma.prnewswire.com/media/616416/Alkermes_plc_Logo.jpg